Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice

C. Wilke, E. Haas, K. Reetz, J. Faber, H. Garcia-Moreno, M.M. Santana, B. van de Warrenburg, H. Hengel, M. Lima, A. Filla, A. Durr, B. Melegh, M. Masciullo, J. Infante, P. Giunti, M. Neumann, J. de Vries, L. Pereira de Almeida, M. Rakowicz, H. JacobiR. Schüle, S.A. Kaeser, J. Kuhle, T. Klockgether, L. Schöls, C. Barro, J. Hübener-Schmid, M. Synofzik

Research output: Contribution to journalArticlepeer-review


With molecular treatments coming into reach for spinocerebellar ataxia type 3 (SCA3), easily accessible, cross-species validated biomarkers for human and preclinical trials are warranted, particularly for the preataxic disease stage. We assessed serum levels of neurofilament light (NfL) and phosphorylated neurofilament heavy (pNfH) in ataxic and preataxic subjects of two independent multicentric SCA3 cohorts and in a SCA3 knock-in mouse model. Ataxic SCA3 subjects showed increased levels of both NfL and pNfH. In preataxic subjects, NfL levels increased with proximity to the individual expected onset of ataxia, with significant NfL elevations already 7.5 years before onset. Cross-sectional NfL levels correlated with both disease severity and longitudinal disease progression. Blood NfL and pNfH increases in human SCA3 were each paralleled by similar changes in SCA3 knock-in mice, here also starting already at the presymptomatic stage, closely following ataxin-3 aggregation and preceding Purkinje cell loss in the brain. Blood neurofilaments, particularly NfL, might thus provide easily accessible, cross-species validated biomarkers in both ataxic and preataxic SCA3, associated with earliest neuropathological changes, and serve as progression, proximity-to-onset and, potentially, treatment-response markers in both human and preclinical SCA3 trials.

Original languageUndefined/Unknown
JournalEMBO Molecular Medicine
Issue number7
Publication statusPublished - 2020

Cite this